GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: h-R3 | THERACIM® | Theraloc®
                                 
                                                         
                            
                            
                            
                                 
                                
                                nimotuzumab is an approved drug (China, India, others (2014)) 
                                                        
                                                    
                                Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: Nimotuzumab is a monoclonal antibody directed agianst the epidermal growth factor receptor (EGFR), being developed as an antineoplastic agent. 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                    Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence analysis using the light chain variable region of nimotuzumab provides a 100% match with sequence 35 from patent US6506883 [1]. Biosimilar drug: Biocon Limited are developing BIOMAb-EGFRTM as a nimotuzumab biosimilar  | 
                                    
| Bioactivity Comments | 
| Patent US6506883 [1] does not include an affinity value for the interaction between nimotuzumab and the EGFR. |